Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin

被引：11

作者：

Kalra, Sanjay ^{[1
]}

机构：

[1] Bharti Hosp & BRIDE, Karnal, India

来源：

DIABETES THERAPY | 2013年 / 4卷 / 02期

关键词：

Basal insulin; Diabetes; Insulin; Insulin analogs; Insulin degludec; CROSS-NATIONAL BENCHMARKING; TO-TARGET TRIAL; NEEDS; 2ND; GLARGINE; PEOPLE; TYPE-2; HYPOGLYCEMIA; VARIABILITY; ATTITUDES; DETEMIR;

D O I：

10.1007/s13300-013-0047-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management.

引用

收藏

页码：167 / 173

页数：7

相关论文

共 21 条

[1]

[Anonymous], 2011, DIABETES

[2]

[Anonymous], DIABETES S1

[3]

[Anonymous], BMJ

[4] Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart [J].

Ashwell, S. G. ;

Gebbie, J. ;

Home, P. D. .

DIABETIC MEDICINE, 2006, 23 (08) :879-886

[5] Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine [J].

Birkeland, Kare I. ;

Home, Philip D. ;

Wendisch, Ulrich ;

Ratner, Robert E. ;

Johansen, Thue ;

Endahl, Lars A. ;

Lyby, Karsten ;

Jendle, Johan H. ;

Roberts, Anthony P. ;

DeVries, J. Hans ;

Meneghini, Luigi F. .

DIABETES CARE, 2011, 34 (03) :661-665

[6] Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking indicators for family members living with people with diabetes [J].

Burns, K. Kovacs ;

Nicolucci, A. ;

Holt, R. I. G. ;

Willaing, I. ;

Hermanns, N. ;

Kalra, S. ;

Wens, J. ;

Pouwer, F. ;

Skovlund, S. E. ;

Peyrot, M. .

DIABETIC MEDICINE, 2013, 30 (07) :778-788

[7] What is the optimal therapy for young males with hypogonadotropic hypogonadism? [J].

Han, T. S. ;

Bouloux, P. M. G. .

CLINICAL ENDOCRINOLOGY, 2010, 72 (06) :731-737

[8] Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes [J].

Heise, T. ;

Hermanski, L. ;

Nosek, L. ;

Feldman, A. ;

Rasmussen, S. ;

Haahr, H. .

DIABETES OBESITY & METABOLISM, 2012, 14 (09) :859-864

[9] Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes [J].

Heise, T ;

Nosek, L ;

Ronn, BB ;

Endahl, L ;

Heinemann, L ;

Kapitza, C ;

Draeger, E .

DIABETES, 2004, 53 (06) :1614-1620

[10] A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes A randomized, controlled trial [J].

Heise, Tim ;

Tack, Cees J. ;

Cuddihy, Robert ;

Davidson, Jaime ;

Gouet, Didier ;

Liebl, Andreas ;

Romero, Enrique ;

Mersebach, Henriette ;

Dykiel, Patrik ;

Jorde, Rolf .

DIABETES CARE, 2011, 34 (03) :669-674